3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
OPAL Fuels said Co-Chief Executive Officer Jonathan Maurer intends to retire on March 31, 2027, and will then serve as a Senior Advisor for an appropriate period. Adam Comora will become the company's sole Chief Executive Officer upon Maurer's retirement. The filing states no new compensation arrangements for Maurer beyond his existing equity awards, and no financial results were included.
Jonathan Maurer notified the company on October 19, 2026 of his intent to retire effective March 31, 2027.
Adam Comora will become sole Chief Executive Officer upon Maurer's retirement.
Maurer will remain available as a Senior Advisor; no new compensation arrangements exist beyond existing equity awards.
The Board has commenced an executive search for a President, who will report to Comora.
HII's board elected former CEO C. Michael Petters as a director effective October 19, 2026, and increased the board from eleven to twelve members. Petters will serve on the Cybersecurity and Finance Committees, and his compensation is a board retainer and deferred stock units, which the filing lists as routine director pay.
Petters was elected to the board effective October 19, 2026, and appointed to the Cybersecurity and Finance Committees.
He previously served as HII president and CEO from March 2011 to March 2022 and as Executive Vice Chairman until his retirement in January 2023.
Annual cash retainer of $130,000, plus $20,000 for each committee role, and an annual equity grant of $195,000 in deferred stock units, prorated for 2026.
Board size increased from eleven to twelve members.
Silvia, Inc. said its Chief Financial Officer Renae Cormier, Chief Operating Officer Megan Pacchia and Chief Legal Officer Kyle Wood will separate from the company, with separation dates no later than October 21, 2026. The company named Catalina Abbey interim CFO and Caroline Hennigar COO, and issued a press release on a cost-cutting initiative expected to deliver more than $10 million in annualized savings.
Three officers leaving: CFO Renae Cormier, COO Megan Pacchia and Chief Legal Officer and Secretary Kyle Wood, each under a Mutual Separation Agreement dated October 20, 2026.
Each departing officer would receive $500,000 in severance paid over six months, plus fully vested Plan shares (258,317 for Wood, 366,392 for Pacchia, 194,495 for Cormier), subject to conditions.
Catalina Abbey, 45, will serve as interim CFO with a $200,000 base salary; Caroline Hennigar, 35, becomes COO with a $250,000 base salary.
Cost-cutting initiative expected to generate more than $10 million in annualized savings, with the full run-rate benefit to follow; details to come with the next scheduled financial update.
Entravision's board appointed Gary Ferrera and Brian Krzanich as directors on October 14, 2026, and increased the board from seven to nine seats. Mr. Ferrera was also named to the Audit Committee, and the filing says both directors are independent under NYSE listing standards.
Gary Ferrera, 64, is a former chief financial officer and was appointed to the Audit Committee.
Brian Krzanich, 66, is president and chief executive officer of Cerence and a former chief executive officer of Intel.
Both directors serve until the 2027 annual meeting and receive standard non-employee director compensation, including a prorated initial restricted stock unit grant.
The filing states there is no arrangement under which either director was selected and no related-party transaction interest.
Inhibikase Therapeutics appointed Scott Wasserman, MD, as a Class III director effective October 19, 2026, and Dennis Berman resigned from the board the same day. The change involves board and committee seats rather than operations, and the company said Berman's resignation was not due to any disagreement with management.
Scott Wasserman, MD, currently Chief Medical Officer of Kailera Therapeutics, joins the board effective October 19, 2026, and will serve on the Compensation Committee.
Wasserman receives an initial new director grant of non-qualified stock options to purchase up to 310,000 shares of common stock.
Dennis Berman resigned from the board effective October 19, 2026, including his roles as Compensation Committee chair and Audit Committee member.
The company's board has determined Wasserman is independent under Nasdaq listing standards and SEC rules.
Apollo Global Management said its board increased its size to 14 directors and appointed Meyer "Micky" Malka, founder and managing partner of Ribbit Capital, to fill the new seat. The appointment and board expansion take effect January 1, 2027, and the filing describes Malka as independent under NYSE listing standards.
Board increased from its current size to 14 directors; Malka appointed to fill the resulting vacancy, effective January 1, 2027
Malka is founder and managing partner of Ribbit Capital and currently serves on the board of Robinhood Markets, Inc.
Apollo states it continues to maintain a two-thirds independent board
Filing reports no related-person transactions requiring disclosure under Item 404(a) of Regulation S-K
AST SpaceMobile entered into a new executive employment agreement with Andrew M. Johnson, its Executive Vice President, Chief Financial Officer and Chief Legal Officer, effective October 14, 2026, superseding his prior agreement. The filing sets out his base salary, bonus and equity eligibility and severance terms, which matter to shareholders as a routine update to a senior officer's compensation arrangements.
Initial term of three years starting October 14, 2026, renewing automatically for one-year terms unless either party gives at least 30 days' notice
Annual base salary of not less than $250,000, subject to annual review by the Compensation Committee
If terminated without Cause, for Good Reason or through non-renewal, severance includes 12 months of base salary continuation and 12 months of subsidized COBRA coverage
Live Oak Bancshares disclosed that Renato Derraik notified the company on October 14, 2026, that he is resigning as Chief Information & Digital Officer of Live Oak Banking Company, to pursue other endeavors. His last day with the bank will be November 6, 2026.
Renato Derraik resigned as Chief Information & Digital Officer of Live Oak Banking Company.
Notice of resignation given to the company on October 14, 2026.
Last day of employment with the bank is November 6, 2026.
The filing gives no successor name and no financial figures.
Northern Trust appointed Rima Qureshi as a director of the company and of its principal subsidiary, The Northern Trust Company, effective October 20, 2026. She joins the Risk Committee and the Technology and Operations Committee, and will receive prorated director equity awards through the 2027 Annual Meeting of Stockholders. The filing describes a board change with no reported financial figures.
Appointed to the Northern Trust Corporation board and The Northern Trust Company board on October 20, 2026
Named to the Risk Committee and the Technology and Operations Committee, effective October 20, 2026
Former executive vice president and chief strategy officer of Verizon Communications, which she joined in 2017; previously spent 23 years at Ericsson
Will receive prorated equity awards under the Non-Employee Director Compensation Plan through the 2027 Annual Meeting
Randall P. Gabe, Senior Vice President and Chief Administrative Officer of Southwest Gas Corporation, told the company on October 20, 2026, that he intends to retire on or before June 1, 2027, after 30 years of service. Until then he will take a new role as Senior Vice President/Business Development, supporting the 2028 Great Basin Expansion project and overseeing the Emerging Technology and Innovation team. The filing states his decision was not the result of any disagreement with the company on operations, policies or practices.
Randall P. Gabe, SVP and Chief Administrative Officer, intends to retire effective on or before June 1, 2027
Gabe has 30 years of service with the company
New role: SVP/Business Development, supporting the 2028 Great Basin Expansion project and overseeing Emerging Technology and Innovation team until retirement
Filing states no disagreements with the company led to the retirement
Vertex Pharmaceuticals appointed Daniel Brennan, a former Chief Financial Officer of Boston Scientific, to its board of directors on October 20, 2026, and expanded the board from ten to eleven members. He also joined the Audit and Finance Committee and received a $400,000 restricted stock unit award that vests in October 2027.
Daniel Brennan joined the board on October 20, 2026; board size increased from ten to eleven members.
Brennan retired in June 2025 as Executive Vice President and Chief Financial Officer of Boston Scientific, a role he held from January 2014.
Brennan received a $400,000 restricted stock unit award vesting in October 2027 and joined the Audit and Finance Committee.
The filing reports no related-person transactions requiring disclosure and no arrangement under which Brennan was appointed.
Whirlpool's board appointed Karin Risi as a director effective immediately on October 19, 2026, and named her to the Human Resources and Finance committees. Risi is a former Vanguard senior executive with more than 30 years of experience in asset and wealth management, and her non-employee director pay is set at a $150,000 annual cash retainer plus $160,000 in annual equity.
Appointed October 19, 2026, effective immediately, with seats on the Human Resources and Finance committees
Annual cash retainer of $150,000 and annual equity compensation of $160,000 in Whirlpool common stock, payable at the annual stockholder meeting
Risi spent 28 years at Vanguard, most recently as managing director and chief strategy and product officer
Clearfield, Inc. said President and CEO Cheri Beranek will retire on March 31, 2027, under a transition agreement dated October 15, 2026. She stays in the CEO role until the earlier of that date or the appointment of a successor, then serves as a non-executive emeritus officer. The company also said fiscal 2026 fourth-quarter and full-year results are expected to be in line with its August 5, 2026 guidance.
Retirement effective March 31, 2027; the board will search for a new CEO with a nationally recognized search firm
Base salary of $483,000 and benefits unchanged during the transition; no future equity awards
2027 incentive bonus opportunity set at 100% of base salary and not prorated
Fiscal 2026 Q4 and full-year results expected in line with August 5, 2026 guidance; report due November 10, 2026
TJX Companies disclosed an October 15, 2026 letter agreement with Senior Executive Vice President and Group President Kenneth Canestrari tied to his planned retirement. He will stop serving as an executive officer on January 31, 2027, and remain employed as a Senior Executive Vice President until his scheduled retirement on April 30, 2027. The filing does not describe a change in company financial results, and the executive transition is planned in advance with a defined timeline.
Agreement dated October 15, 2026 extends Canestrari's employment agreement term to April 30, 2027
Canestrari stops serving as an executive officer effective January 31, 2027
He will not participate in the Management Incentive Plan or LRPIP for performance periods beginning fiscal 2028 or later, and will not receive new SIP equity grants
He keeps existing LRPIP and SIP award opportunities under special service recognition benefits and remains bound by non-compete and non-solicitation obligations
Newell Brands appointed Guillermo Beade as Chief Operating Officer, effective October 26, 2026, reporting to President and CEO Chris Peterson. He will oversee global sales, central marketing and supply chain, and will join the Executive Committee. The filing sets out his base salary, bonus target and equity grant, which shareholders can review in the compensation terms.
Effective date is October 26, 2026; Beade reports to CEO Chris Peterson
Annual base salary of $830,000 with a target bonus of 105% of earned base salary
Initial LTIP grant with a target value of $1.4 million, on or promptly after the effective date
Most recently President, Consumer Brands North America at SC Johnson, from January 2024 until June 2026
Suja Life increased its Board from seven to nine members and appointed Robert B. Engel and Zahir Ibrahim as directors effective October 16, 2026. Engel also joined the Audit Committee, and both were designated by affiliates of Paine Schwartz Partners, LLC, the Company's principal stockholder. The filing describes the appointments as adding financial, accounting and capital markets expertise, but it discloses no financial results or guidance.
Board expanded from seven to nine members; Engel and Ibrahim appointed effective October 16, 2026
Engel, former CEO of CoBank, joins the Audit Committee; Ibrahim is a former CFO of BARK, Annie's and KIND
Both directors were designated by affiliates of Paine Schwartz Partners, LLC under a Director Designation Agreement dated May 8, 2026
Each receives a $75,000 annual cash retainer and a $100,000 grant-date-value RSU award, prorated for service time
StubHub Holdings' board appointed Andrew Raab as a director on October 16, 2026, to fill an existing vacancy, effective immediately, with a term ending at the 2027 annual meeting. The filing says he is not expected to serve on any board committee, and it discloses prior financial dealings with the company, including a 2025 preferred stock purchase and a 2026 consulting agreement.
Appointed October 16, 2026, to fill an existing vacancy; term expires at the 2027 annual meeting of stockholders
Not expected to serve on any board committee
Consulting agreement dated March 27, 2026, with a three-year term; RSUs granted with an aggregate grant date fair value of $200,000
On August 15, 2025, bought 2,000 Series O redeemable preferred shares at $1,000 per share (about $2.0 million), which converted into 93,617 Class A common shares on March 17, 2026
PDS Biotechnology reported that four directors resigned from its Board effective October 18, 2026, and the Board appointed three new directors that day to fill three of the four vacancies. The Board fixed its size at seven directors and reconstituted its committees, which matters to shareholders because it changes who oversees audit, compensation and governance.
Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley resigned effective October 18, 2026; the filing says none resulted from a disagreement with the Company.
Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel were appointed directors on October 18, 2026, and the Board set its size at seven.
Each new director received a nonqualified stock option to purchase 22,700 shares, vesting in three annual installments.
James Banaag chairs the Audit Committee and is designated an audit committee financial expert; Bruce Wendel chairs the Nominating and Corporate Governance Committee.
Laser Photonics (LASE) appointed Timothy Peterman as permanent Chief Financial Officer and Secretary, effective October 6, 2026, after he had served as acting CFO since September 8, 2026. His October 15, 2026 employment agreement sets a three-year term, a $300,000 base salary and equity awards tied to 80% of that salary, which will affect the company's executive compensation costs.
Peterman has served as acting CFO since September 8, 2026; the permanent appointment is effective October 6, 2026.
Employment agreement dated October 15, 2026 has a three-year term, a $300,000 base salary and a one-time $80,000 relocation payment subject to repayment if he leaves early.
Fiscal 2027 bonus opportunity is up to 60% of base salary; equity awards are valued at 80% of base salary with three-year vesting.
If terminated without cause or for good reason on or after the first anniversary of the effective date, he receives nine months of base salary and 12 months of COBRA reimbursement.
Insmed appointed two independent directors, Paul Hudson, former CEO of Sanofi, and Utpal Koppikar, CFO of Verily Health, effective October 19, 2026. The filing describes standard director compensation, including an RSU grant with a grant date fair value of approximately $585,000 to each director, and places the new directors on the Compensation and Audit Committees.
Paul Hudson was CEO of Sanofi S.A. from September 2019 through February 2026 and CEO of Novartis Pharmaceuticals from 2016 to 2019; he joins the Compensation Committee.
Utpal Koppikar has been CFO of Verily Health Inc. since April 2023 and was EVP and CFO at Atara Biotherapeutics from 2018 to 2023; he joins the Audit Committee.
Each director receives an annual cash retainer of $65,000, prorated for 2026, plus an RSU grant of approximately $585,000 that vests in equal parts over three years.
The appointments were made by the Board on October 16, 2026, and announced in a press release dated October 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.